230 related articles for article (PubMed ID: 22245905)
21. Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma.
Yang SL; Liu LP; Yang S; Liu L; Ren JW; Fang X; Chen GG; Lai PB
Br J Surg; 2016 May; 103(6):716-724. PubMed ID: 26996727
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
Paul SB; Sahu P; Sreenivas V; Nadda N; Gamanagatti SR; Nayak B; Shalimar S; Acharya SK
Scand J Gastroenterol; 2019 Sep; 54(9):1132-1137. PubMed ID: 31483691
[No Abstract] [Full Text] [Related]
25. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
Yau T; Yao TJ; Chan P; Wong H; Pang R; Fan ST; Poon RT
Oncologist; 2011; 16(9):1270-9. PubMed ID: 21885876
[TBL] [Abstract][Full Text] [Related]
26. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
27. Predictive Factors of Tumor Recurrence and Survival in Patients with Hepatocellular Carcinoma treated with Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Grasu M; Pâslaru L; Dumitru R; Lupescu I; Constantin G; Croitoru A; Gheorghe L
J Gastrointestin Liver Dis; 2018 Dec; 27(4):409-417. PubMed ID: 30574623
[TBL] [Abstract][Full Text] [Related]
28. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.
Nanashima A; Taura N; Abo T; Ichikawa T; Sakamoto I; Nagayasu T; Nakao K
Dig Dis Sci; 2011 Oct; 56(10):3086-100. PubMed ID: 21706206
[TBL] [Abstract][Full Text] [Related]
29. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Jeong Y; Yoon SM; Han S; Shim JH; Kim KM; Lim YS; Lee HC; Kim SY; Park JH; Lee SW; Ahn SD; Choi EK; Kim JH
PLoS One; 2015; 10(8):e0135298. PubMed ID: 26252472
[TBL] [Abstract][Full Text] [Related]
30. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
[TBL] [Abstract][Full Text] [Related]
31. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
32. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.
Leerapun A; Suravarapu SV; Bida JP; Clark RJ; Sanders EL; Mettler TA; Stadheim LM; Aderca I; Moser CD; Nagorney DM; LaRusso NF; de Groen PC; Menon KV; Lazaridis KN; Gores GJ; Charlton MR; Roberts RO; Therneau TM; Katzmann JA; Roberts LR
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):394-402; quiz 267. PubMed ID: 17368240
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
34. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
Negri F; Gnetti L; Pedrazzi G; Silini EM; Porta C
Future Oncol; 2021 Sep; 17(27):3579-3584. PubMed ID: 34155918
[TBL] [Abstract][Full Text] [Related]
36. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
38. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
39. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
40. Alpha fetoprotein changes predict hepatocellular carcinoma survival beyond the Milan criteria after hepatectomy.
Shen JY; Li C; Wen TF; Yan LN; Li B; Wang WT; Yang JY; Xu MQ
J Surg Res; 2017 Mar; 209():102-111. PubMed ID: 28032546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
